NTRK3(TRKC)
Sign in to save this workspaceUniProt Q16288 · PDB · AlphaFold · Substrate: pEY · Clone: catalytic domain (aa 510-825)
Top inhibitors
| # | Drug | Inhibition | Residual | KISS | Gini |
|---|---|---|---|---|---|
| 1 | Pralsetinib | 99.4% | 0.6% | 93.43 | 0.643 |
| 2 | Alpelisib | 99.3% | 0.7% | 97.22 | 0.720 |
| 3 | Gilteritinib | 99.0% | 1.0% | 88.97 | 0.506 |
| 4 | Repotrectinib | 98.9% | 1.1% | 84.21 | 0.608 |
| 5 | Entrectinib | 98.8% | 1.2% | 93.69 | 0.671 |
| 6 | Larotrectinib | 98.1% | 1.9% | 99.25 | 0.710 |
| 7 | Tenalisib | 98.1% | 1.9% | 97.98 | 0.702 |
| 8 | Crizotinib | 97.3% | 2.7% | 91.39 | 0.581 |
| 9 | Nintedanib | 96.7% | 3.3% | 90.23 | 0.608 |
| 10 | Pacritinib | 96.7% | 3.3% | 88.64 | 0.452 |
| 11 | Ponatinib | 96.7% | 3.3% | 78.23 | 0.534 |
| 12 | Tivozanib | 96.1% | 3.9% | 92.42 | 0.673 |
| 13 | Bosutinib | 95.6% | 4.4% | 87.22 | 0.555 |
| 14 | Sunitinib | 95.4% | 4.6% | 91.73 | 0.524 |
| 15 | Midostaurin | 95.1% | 4.9% | 78.64 | 0.500 |
| 16 | Darovasertib | 94.5% | 5.5% | 96.99 | 0.719 |
| 17 | Alectinib | 94.2% | 5.8% | 95.49 | 0.651 |
| 18 | Defactinib | 91.7% | 8.3% | 92.68 | 0.450 |
| 19 | Lorlatinib | 91.3% | 8.7% | 97.24 | 0.694 |
| 20 | Tepotinib | 86.2% | 13.8% | 99.75 | 0.727 |
Paralog block
No paralog group registered for this kinase.
EMT expression
- Mesenchymal log2(TPM+1): 1.11
- Epithelial log2(TPM+1): 0.28
- Fold change: 0.83
- Status: No significant change
Selectivity landscape vs inhibition on NTRK3
Each point is one of the 92 approved drugs; color = inhibition % on NTRK3.
Variants (5)
3D structure
Embedded NGL viewer pulls a representative PDB entry (or AlphaFold model if no experimental structure is registered). Heavy bundle — loaded only on demand.
Annotations
Sign in to read and post annotations.
Loading…